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ABSTRACT
Introduction: Metastatic colorectal cancer is rarely
curable. Improving quality of life is therefore a key
treatment goal. We report quality of life for patients
with RAS wild-type metastatic colorectal cancer in the
PRIME study.
Methods: A randomised phase 3 open-label study of
first-line panitumumab+FOLFOX4 vs FOLFOX4 enrolled
adults with untreated metastatic colorectal cancer and
an Eastern Cooperative Oncology Group performance
status of 0–2. This analysis includes patients with wild-
type RAS tumours (n=505). Quality of life (prespecified
end point) was assessed using the EuroQoL 5-domain
health state index and overall health rating in all
patients and by early tumour shrinkage status (≥30%
reduction in size by week 8; exploratory end point).
Differences in quality of life were assessed using
analysis of covariance and a mixed-effect piecewise
linear model, and were also analysed by skin toxicity
severity.
Results: There were no statistically significant
differences between treatment arms from baseline to
progression or to discontinuation. Grade 3+ skin
toxicity was reported by 38% of patients receiving
panitumumab+FOLFOX4 and 2% receiving FOLFOX4
alone. There were no significant differences in quality
of life between patients with grade 0–2 skin toxicity
and those with grade 3+ skin toxicity. More patients
receiving panitumumab+FOLFOX4 vs FOLFOX4 had
early tumour shrinkage (p<.001). In patients with
tumour symptoms at baseline, there were statistically
significant improvements in quality of life in those with
early tumour shrinkage versus those without early
tumour shrinkage.
Conclusions: Addition of panitumumab to FOLFOX4
in first-line therapy for metastatic colorectal cancer
prolongs survival and has no negative effect on overall
quality of life compared with FOLFOX4 alone. Specific
quality of life assessments for skin toxicity should be
included in study designs to better define the direct
effect of these adverse events.
Trial registration number: NCT00364013.
INTRODUCTION
Optimal anticancer treatment involves a
balance between efﬁcacy and safety,1 as
adverse events can have a negative effect on
quality of life (QoL).2 3 Despite recent
advances, the curative treatment of metastatic
colorectal cancer (mCRC) is limited to a sub-
group of patients undergoing complete
resection, and improvement of QoL is there-
fore an important treatment goal in patients
with mCRC.4 5
Panitumumab is a fully human monoclonal
antibody (mAb) targeting the epidermal
growth factor receptor (EGFR),6 which is
indicated in combination with FOLFOX or
FOLFIRI for the ﬁrst-line treatment of
patients with RAS wild-type (WT) mCRC in
Europe.7 The efﬁcacy and safety of ﬁrst-line
panitumumab in combination with
Key questions
What is already known about this subject?
Panitumumab in first-line therapy can improve sur-
vival in patients with wild-type RAS metastatic colo-
rectal cancer, but is associated with skin toxicities
characteristic of epidermal growth factor receptor
(EGFR) inhibitors.
What does this study add?
Addition of panitumumab to FOLFOX4 chemother-
apy in first-line therapy for RAS wild-type metastatic
colorectal cancer has no negative effect on overall
quality of life compared with FOLFOX4 alone.
How might this impact on clinical practice?
Physicians can be reassured that the survival bene-
fits associated with first-line panitumumab in RAS
wild-type metastatic colorectal cancer do not come
at the expense of impaired quality of life.
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FOLFOX4 were evaluated in the PRIME study,8 9 in
which panitumumab signiﬁcantly improved overall sur-
vival (OS 26.0 months) versus FOLFOX4 alone
(20.2 months; p=.04) in patients with mCRC WT for
KRAS and NRAS exons 2–4 (RAS WT).9 In addition,
more patients receiving panitumumab+FOLFOX4 vs
FOLFOX4 had ≥30% tumour shrinkage at week 8, while
objective response rate, duration of response and depth
of response were also improved in the panitumumab
group.10 Panitumumab treatment was well tolerated, but
was associated with adverse events typical of EGFR inhi-
bitors, including skin toxicity and diarrhoea.8 Notably,
skin toxicity has been linked with improved survival out-
comes in patients with mCRC receiving panitumumab
+FOLFOX4.11 This is, however, an area of debate, with
analyses suggesting that skin toxicity alone cannot be
used as a surrogate marker for efﬁcacy. For example, in
the analysis of data from the PRIME study, duration of
treatment was a confounding factor, with patients who
received panitumumab remaining on treatment longer
than those receiving FOLFOX4 alone. We report prespe-
ciﬁed tertiary QoL end points from the PRIME study for
patients with RAS WT mCRC, including exploratory ana-
lyses of the impact of early tumour shrinkage (ETS) and
skin toxicity on QoL.
METHODS
Study design and patients
PRIME (ClinicalTrials.gov: NCT00364013) was a rando-
mised (1:1), open-label phase 3 study of ﬁrst-line panitu-
mumab+FOLFOX4 vs FOLFOX4 alone in patients with
mCRC. The study was conducted in 133 study centres in
18 countries (Argentina, Australia, Belgium, Brazil,
Canada, Chile, Costa Rica, the Czech Republic, France,
Hungary, Italy, Latvia, Mexico, Poland, South Africa,
Spain, Switzerland, the UK). The ﬁrst patient was
enrolled in August 2006 (ﬁrst participant enrolled), and
the ﬁnal data cut-off date was August 2010.
Panitumumab was given as an intravenous infusion of
6.0 mg/kg on the ﬁrst day of each 14-day cycle.
Participants were randomised using an interactive voice
response system, and randomisation was stratiﬁed by
geographic region (Western Europe, Canada and
Australia vs rest of the world) and Eastern Cooperative
Oncology Group (ECOG) performance status (PS 0 or 1
vs 2). Each patient was assigned a unique identiﬁcation
number used to identify that patient throughout the
study. Details of the study design and inclusion criteria
have been published previously.8
The primary end point was progression-free survival
(PFS), with secondary end points including OS, object-
ive tumour response and safety. Although the study was
originally designed to test treatment effect in all rando-
mised patients, it was amended to compare PFS and OS
according to KRAS status prior to any efﬁcacy analyses.
Sample size was originally set at 900 patients, assuming
that all time-to-event end points are exponentially
distributed. The sample size was revised to 1150 when
the protocol was revised to assess the primary end point
in patients with WT KRAS tumours only (assumed preva-
lence, 55%). This is based on a PFS HR of 0.714 and a
median PFS of 12 months in the control arm.
Eligible patients were aged ≥18 years with previously
untreated metastatic adenocarcinoma of the colon or
rectum, and had an ECOG PS of 0–2. The protocol was
approved by the ethics committees at participating sites
and adhered to all ethical guidelines, and all patients
signed informed consent before any study-related proce-
dures were performed. The present analysis focuses
on patients with RAS WT mCRC (ie, tumours WT for
KRAS/NRAS exon 2 (codons 12 and 13), exon 3 (codons
59 and 61) and exon 4 (codons 117 and 146)).9 Mutation
analysis was performed using Sanger sequencing and
SURVEYOR/WAVE laboratory-developed testing, as
described previously.12
QoL end points and analysis
QoL was assessed as a prespeciﬁed tertiary end point
during PRIME, using the EuroQoL 5-domain (EQ-5D)
health state index (HSI) and overall health rating
(OHR) measures. HSI scores range from −0.594 to 1.0
(higher scores represent better health, with 1.0 equiva-
lent to perfect health). The OHR comprises a 0–100
visual analogue scale, with 0 representing the ‘worst
imaginable health state’ and 100 representing the ‘best
imaginable health state’. QoL was assessed ≤7 days
before randomisation and every 4 weeks until disease
progression, with a ﬁnal assessment at a safety follow-up
visit.
Between-treatment differences in QoL were assessed
from baseline to disease progression, and to discontinu-
ation of ﬁrst-line treatment, using analysis of covariance
(ANCOVA). Treatment-by-covariate interactions
(between treatment and baseline QoL score, between
treatment and baseline ECOG score, and between treat-
ment and region) was tested at the 5% level and those
that were found to be signiﬁcant were retained in the
ﬁnal model. Changes in QoL from baseline to discon-
tinuation of ﬁrst-line treatment, and between-treatment
differences, were also assessed using a mixed-effect
model adjusted for worst grade skin toxicity (ie, nail
changes, erythema, pruritus, acne, rash and ulceration;
grade 0–2 vs grade 3+), baseline QoL score and time
(QoL assessment week). Random effects for intercept
and time were also included. In the HSI model, the ﬁve
subscales (anxiety/depression, mobility, pain/discom-
fort, self-care and usual activities) were evaluated
separately.
The primary QoL analyses were conducted on the
subset of patients in the intent-to-treat analysis set who
had a baseline QoL assessment and at least one postba-
seline QoL assessment. For this analysis, the minimally
important differences (MIDs) were deﬁned as 0.08 for
HSI and 7 for OHR.13 Changes in QoL were also
assessed in subgroups of patients with and without ETS,
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both in the overall population and in patients with
tumour-related symptoms at baseline (deﬁned as EQ-5D
pain/discomfort scale score >1). Tumour size and
response were measured as described previously,10 and
ETS was deﬁned as a decrease of ≥30% in tumour size
at week 8.
RESULTS
Patients
Of the 1183 patients enrolled in PRIME, 505 had RAS
WT mCRC (patient disposition shown in online
supplementary ﬁgure S1). Baseline demographics,
disease characteristics and QoL scores were similar
between treatment groups (see online supplementary
table S1). Overall rates of compliance with the QoL
assessments (expressed as evaluable vs expected assess-
ments) were 57% for HSI and OHR.
Quality of life
When analysed by ANCOVA, there were no statistically
signiﬁcant differences between the panitumumab
+FOLFOX4 and FOLFOX4 arms in HSI or OHR scores
from baseline to progression or to discontinuation
(table 1 and ﬁgure 1). In total, 450 patients (89%) were
included in the mixed-effect model. In this model, there
were no statistically signiﬁcant differences between pani-
tumumab+FOLFOX4 and FOLFOX4 alone in terms of
HSI or OHR scores from baseline to discontinuation, or
on any subscale of the HSI (table 2). There were,
however, individual change scores for speciﬁc HSI items
in both treatment arms that were greater than the MID,
including improvements in mobility and decreases in
anxiety/depression in both treatment arms (table 2).
Analysis of QoL by skin toxicity
Overall, 94 patients (38%) receiving panitumumab
+FOLFOX4 and 6 patients (2%) receiving FOLFOX4
alone experienced grade 3+ skin toxicity. The most
common skin toxicity adverse event was rash (panitumu-
mab+FOLFOX4, 56%; FOLFOX4, 8%; see online
supplementary table S2), which led to discontinuation
in 10 patients (4%) in the panitumumab+FOLFOX4
arm and 3 patients (1%) in the FOLFOX4 arm. Other
skin toxicities that led to discontinuation in more than
one patient were dermatitis acneiform (n=6; 3%) and
paronychia (n=5; 2%), all in the panitumumab
+FOLFOX4 arm.
In the mixed-effect model of QoL by skin toxicity, 79%
of patients overall had a worst-grade skin toxicity of <3.
There were no signiﬁcant differences in QoL outcomes
in patients with grade 0–2 skin toxicity and those with
grade 3+ skin toxicity (table 3). Again, there were
improvements in mobility and decreases in anxiety/
depression greater than the MID in both treatment arms.
Analysis of QoL by ETS
More patients receiving panitumumab+FOLFOX4
(59%) versus FOLFOX4 (38%) had ETS of ≥30%
(p<.001). In patients with tumour symptoms at baseline,
there were statistically signiﬁcant improvements in QoL
in those with ETS versus those without ETS (table 4). In
addition, improvement from baseline in HSI score in
symptomatic patients with ETS (+0.096) was greater than
the MID. In the overall population (ie, irrespective of
symptomatic disease at baseline), there was no differ-
ence in QoL for those with ETS versus those without
ETS.
DISCUSSION
The maintenance of QoL is an important component of
cancer management, as codiﬁed in the recent European
Society for Medical Oncology Magnitude of Clinical
Beneﬁt Scale (ESMO-MCBS).5 Indeed, studies have
shown that QoL is important, not just for the patient’s
well-being, but also because it can inﬂuence survival and
response to therapy.14 The relationship between ETS
and QoL is, however, unknown. We therefore conducted
an analysis of QoL in patients receiving ﬁrst-line treat-
ment for mCRC with FOLFOX4 with or without panitu-
mumab in the phase 3 PRIME study.
While addition of panitumumab to FOLFOX4 in ﬁrst-
line RAS WT mCRC is associated with a high incidence
Table 1 Analysis of change in EuroQoL 5-domain (EQ-5D) scores from baseline
Panitumumab+FOLFOX4 FOLFOX4 Difference
Disease progression
n 223 221
Health state index 0.74 (0.70 to 0.78) 0.76 (0.73 to 0.80) −0.02 (−0.06 to 0.01)
n 222 216
Overall health rating 72.5 (69.6 to 75.4) 74.0 (71.1 to 76.9) −1.48 (−3.96 to 1.01)
Discontinuation
n 222 220
Health state index 0.75 (0.72 to 0.79) 0.77 (0.74 to 0.81) −0.02 (−0.05 to 0.01)
n 221 215
Overall health rating 73.0 (70.2 to 75.8) 74.5 (71.7 to 77.3) −1.48 (−3.87 to 0.91)
Analysis of covariance (ANCOVA) analysis of weighted mean EQ-5D health state index and overall health rating scores from baseline to
disease progression and from baseline to discontinuation of first-line therapy.
Values are least squares means (95% CIs).
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Figure 1 Analysis of treatment difference by study week. ANCOVA analysis of treatment difference (95% CIs) by study week
in (A) EQ-5D health state index and (B) overall health rating scores, from baseline to discontinuation of first-line therapy.
Table 2 Change from baseline to discontinuation of treatment in EuroQoL 5-domain (EQ-5D) scores by treatment arm
Panitumumab+FOLFOX4
(n=232)*
FOLFOX4
(n=224)* Difference p Value
Health state index −0.005 (−0.027 to 0.017) 0.006 (−0.022 to 0.034) −0.011 (−0.042 to 0.020) 0.50
Anxiety/depression −0.117 (−0.167 to −0.066) −0.115 (−0.181 to −0.049) −0.001 (−0.075 to 0.073) 0.98
Mobility 0.123 (0.076 to 0.171) 0.145 (0.086 to 0.204) −0.0214 (−0.083 to 0.041) 0.50
Pain/discomfort −0.009 (−0.059 to 0.042) −0.037 (−0.103 to 0.028) 0.029 (−0.044 to 0.102) 0.44
Self-care 0.098 (0.059 to 0.137) 0.055 (0.006 to 0.103) 0.0431 (−0.008 to 0.094) 0.10
Usual activities 0.078 (0.023 to 0.132) 0.015 (−0.056 to 0.086) 0.062 (−0.017 to 0.142) 0.12
Overall health rating −0.906 (−2.773 to 0.960) 0.734 (−1.674 to 3.142) −1.640 (−4.257 to 0.976) 0.22
Mixed-effect model of change from baseline to discontinuation of treatment in EQ-5D health state index and overall health rating scores.
Values are least squares means (95% CIs).
*Actual patient numbers differed for each scale/subscale.
Table 3 Change from baseline to discontinuation of treatment in EuroQoL 5-domain (EQ-5D) scores by worst skin toxicity
grade
Worst skin toxicity grade <3
(n=360)*
Worst skin toxicity grade ≥3
(n=96)* Difference p Value
Health state index 0.007 (−0.012 to 0.025) −0.006 (−0.040 to 0.029) 0.0123 (−0.026 to 0.050) 0.52
Anxiety/depression −0.125 (−0.167 to −0.082) −0.107 (−0.187 to −0.027) −0.018 (−0.108 to 0.072) 0.70
Mobility 0.130 (0.088 to 0.171) 0.138 (0.068 to 0.209) −0.009 (−0.085 to 0.067) 0.82
Pain/discomfort −0.025 (−0.067 to 0.018) −0.021 (−0.101 to 0.058) −0.003 (−0.092 to 0.086) 0.94
Self-care 0.077 (0.043 to 0.110) 0.076 (0.018 to 0.134) 0.001 (−0.062 to 0.063) 0.98
Usual activities 0.059 (0.013 to 0.105) 0.034 (−0.052 to 0.120) 0.025 (−0.071 to 0.121) 0.61
Overall health rating −0.022 (−1.609 to 1.565) −0.150 (−3.037 to 2.737) 0.128 (−3.034 to 3.289) 0.94
Mixed-effect model of change from baseline to discontinuation of treatment in EQ-5D health state index and overall health rating scores.
Values are least squares means (95% CIs).
*Actual patient numbers differed for each scale/subscale.
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of skin toxicity, there was no negative impact on global
QoL. While skin toxicity might be expected to have a
negative impact on QoL, our results are consistent with
previous studies of the EGFR inhibitors panitumumab
and cetuximab in mCRC. For example, similar results
were seen in an earlier analysis of data from patients
with WT KRAS mCRC in the PRIME study,15 while
studies of ﬁrst-line FOLFIRI combined with panitumu-
mab or cetuximab have shown no negative effect on
QoL or social functioning during treatment.16–18
Similarly, addition of panitumumab to second-line
FOLFIRI treatment resulted in a signiﬁcant improve-
ment in PFS without compromising QoL.15 In a study of
the psychological effects associated with cetuximab treat-
ment (n=80), psychological distress was present in 41%
of patients.19 Distress was linked with overall QoL, but
not with rash, which did not affect psychological status
or social life. Furthermore, a recent quality-adjusted
time without symptoms of disease or toxicity (Q-TWiST)
analysis from the PRIME study showed that panitumu-
mab+FOLFOX4 signiﬁcantly improved quality-adjusted
survival time compared with FOLFOX4 alone (20.5 vs
18.2 months, respectively; p=0.025).20 The ESMO-MCBS
is a standardised and validated approach to stratify the
magnitude of clinical beneﬁt that can be expected from
anticancer therapies. A recent analysis of therapies for
ﬁrst-line mCRC provides additional conﬁrmation of the
overall clinical beneﬁt of panitumumab: panitumumab
scored 4/5, representing ‘a high level of proven clinical
beneﬁt’ in terms of both prolonged survival and
improved QoL.5
The QoL scales used in these studies, including the
EQ-5D, are measures of global QoL and are not speciﬁc
for skin toxicity. In patients treated with panitumumab in
the PRIME study, therefore, the impact of rash-related
events may have been balanced by favourable antitumour
treatment-related effects. For example, patients with
advanced cancer may consider skin rash to be part of
their overall condition, and they may feel that skin rash is
a marker of treatment efﬁcacy.19 It is also possible that the
beneﬁcial effects of treatment may outweigh skin-related
side effects.3 This is supported by our analysis of ETS, in
which patients with tumour-related symptoms at baseline
who experienced ETS showed a statistically meaningful
improvement in QoL compared with those who did not
have ETS. These important data add to the idea that
achieving early reductions in tumour load is associated
with symptomatic beneﬁt for patients.
The strengths of this study include its randomised
design and international recruitment, as well as the use
of planned QoL assessments with internationally vali-
dated tools available in local languages. The main weak-
ness of the study is the use of global QoL instruments.
The lack of a QoL difference associated with different
grades of adverse events suggests that tools speciﬁc for
skin-related events are required to assess the direct effect
of skin toxicity on QoL for patients receiving treatment
with EGFR inhibitors. One such instrument is the
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Dermatology Life Quality Index, which has previously
been used to assess the impact of toxicities such as hair
loss, hyperpigmentation and dry skin, in patients receiv-
ing cancer chemotherapy.21 It should also be noted that
other drug-related adverse events may also affect QoL.
For example, hypomagnesaemia affects QoL by causing
muscle cramps and spasms, both directly and indirectly
as a result of secondary hypocalcaemia. An analysis of
QoL by muscle-related symptoms (with or without mag-
nesium levels) may therefore also be of interest. Finally,
disease progression itself may affect QoL, which was not
systematically analysed in the present study.
In conclusion, the addition of panitumumab to
FOLFOX4 in ﬁrst-line RAS WT mCRC improves OS9
with no negative effect on overall QoL, despite the high
incidence of skin toxicity. Skin toxicity of grade 3+
appeared to have a similar impact on QoL outcomes as
skin toxicity of grade 0–2. In patients with tumour-
related symptoms, those with ETS experienced signiﬁ-
cant improvements in QoL compared with those who
did not achieve ETS. In future studies, QoL tools spe-
ciﬁc for skin-related events may be required to assess the
direct effect of skin toxicity on QoL for patients receiv-
ing EGFR inhibitors.
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